ABOUT US

Global Leader of Cancer Treatments

Leadership

  • CEO

    CEO

    Global Business Development / Management

    Tai (Tae Hun) Kim

    1. Boryung Pharm. new drug(Kanarb) global biz team; Head
    2. Huya bioscience San Diego, Licensing part
  • GLOBAL

    VP

    Global Business Development / Management

    Charlie (SiChul) Roh

    1. GE healthcare marketing team
    2. Boryung Pharm. overseas biz team
  • GLOBAL

    VP

    Clinical R&D Head

    James JUN M.D.

    1. Boryung Biopharma development team; Head
    2. Pharmedix&Pharvis; CEO/VP
    3. KT&G Life science; President
    4. Boryung Pharm R&D Center team/Kanarb BD; Head
  • GLOBAL

    EVP, R&D Technical

    Director (CTO)

    Y.R. HONG Ph. D.

    1. CrystalGenomics R&D Center Head
    2. Tanabe Pharm (Japan), New Drug Development Researcher
    3. Leukemia, Anemia candidate L/O, Total $500M Deal
    4. Medicinal Chemistry
  • GLOBAL

    Vice President

    R&D Center / Pharmacology Head

    Juneui PARK, Ph. D.

    1. JW CreaGene research institute
    2. Genexine clinical development team; Team leader
    3. Memorial Sloan-Kettering Cancer Center (NY), research associate (Dendritic cell, NKT cell)
    4. Roswell Park Cancer Institute (NY) Ph.D., Biochemistry & Biophysics
  • GLOBAL

    Director

    R&D Business Head

    Kyungwan NAM , Ph. D.

    1. SamJin Pharm. R&D Center, pharmaceutical research; Head
    2. Boryung Pharm. R&D Center, pharmaceutical research; Team leader
    3. DaeWoong Pharm. R&D Center; Senior researcher
    4. Chungnam national University, Ph.D., Pharmacy
  • GLOBAL

    Managing Director

    R&D Center / Discovery Head

    Changhee PARK, Ph.D.

    1. Hanmi research center NCE/ICE discovery team, oncology pipeline discovery & development, medicinal chemistry; Project leader
    2. Chung-ang University, Ph.D., Pharmacy
  • GLOBAL

    Managing Director

    Strategic Planning Division (CFO)

    M.Y. JUNG

    1. Precision Biosensor Strategic Planning Team Leader
    2. SamSung Bioepis Long-term Strategy T/F
    3. Nemo Partners SCG Strategic Consulting